Literature DB >> 16415636

Hypertension--a treatable component of the cardiometabolic syndrome: challenges for the primary care physician.

Camila M Manrique1, Guido Lastra, John Palmer, Craig S Stump, James R Sowers.   

Abstract

Patients with the cardiometabolic syndrome (CMS) have an adverse cardiovascular risk factor profile, placing them at increased risk of stroke, coronary artery disease, chronic kidney disease, and type 2 diabetes mellitus. Although no specific treatments for CMS are available per se, prompt recognition and treatment of the individual components of the condition can prevent or delay the development of comorbidities. Primary care physicians are ideally positioned to identify patients with CMS and implement early intervention strategies. Hypertension contributes to many complications of CMS, and rigorous blood pressure control will help to delay or prevent end-organ vascular damage. Achieving blood pressure control to current guideline standards should be eagerly sought in the majority of patients through a combination of lifestyle modifications and appropriate pharmacologic therapy. Antihypertensive drug choice should be personalized, taking into account the CMS determinants present and any compelling indications for specific agents. As an initial approach, a thiazide diuretic is suitable for most cases of uncomplicated hypertension, although many patients will require additional antihypertensives from other classes to achieve their blood pressure goal. It is predicted that, due to the increase in unhealthy lifestyles, the prevalence of CMS will rise in the coming years. Therefore, by meeting the challenge of attaining and maintaining blood pressure control in patients with CMS, primary care physicians have the unique opportunity to markedly improve the health of the nation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415636      PMCID: PMC8109675          DOI: 10.1111/j.1524-6175.2006.05379.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  66 in total

1.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease: the end of the beginning.

Authors:  Gerald Reaven
Journal:  Circulation       Date:  2005-11-15       Impact factor: 29.690

3.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

4.  Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program.

Authors:  Robert Ratner; Ronald Goldberg; Steven Haffner; Santica Marcovina; Trevor Orchard; Sarah Fowler; Marinella Temprosa
Journal:  Diabetes Care       Date:  2005-04       Impact factor: 19.112

Review 5.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 6.  Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects.

Authors:  M H Weinberger
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

7.  Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease.

Authors:  N Koren-Morag; U Goldbourt; D Tanne
Journal:  Stroke       Date:  2005-06-02       Impact factor: 7.914

8.  Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.

Authors:  M Kochar; R Guthrie; J Triscari; K Kassler-Taub; R A Reeves
Journal:  Am J Hypertens       Date:  1999-08       Impact factor: 2.689

9.  Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults.

Authors:  Shaista Malik; Nathan D Wong; Stanley S Franklin; Tripthi V Kamath; Gilbert J L'Italien; Jose R Pio; G Rhys Williams
Journal:  Circulation       Date:  2004-08-23       Impact factor: 29.690

10.  The metabolic syndrome and chronic kidney disease in U.S. adults.

Authors:  Jing Chen; Paul Muntner; L Lee Hamm; Daniel W Jones; Vecihi Batuman; Vivian Fonseca; Paul K Whelton; Jiang He
Journal:  Ann Intern Med       Date:  2004-02-03       Impact factor: 25.391

View more
  2 in total

1.  Homocysteine and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in Tunisian patients with severe coronary artery disease.

Authors:  Lakhdar Ghazouani; Nesrine Abboud; Nabil Mtiraoui; Walid Zammiti; Faouzi Addad; Haitham Amin; Wassim Y Almawi; Touhami Mahjoub
Journal:  J Thromb Thrombolysis       Date:  2008-01-19       Impact factor: 2.300

2.  Patterns and associated health services costs of antihypertensive drug modifications.

Authors:  Shadi S Saleh; Steven Szebenyi; Judith A Carter; Chris Zacher; Dan Belletti
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.